Smithwise and Catapult have joined teams to become Archimedic! Read More.
Contact

Epinephrine Delivery System

A 2018 study by the Univ. of Southern California showed that half of adults with severe food allergies haven't had their EpiPen® or other auto-injector with them during their most severe attack. 

Dr. Edmund Pribitkin, CMO of Thomas Jefferson University Hospitals, approached Archimedic (then Smithwise) with a proposed solution--embedding an auto-injector for epinephrine into the case of a smartphone. 

This project is based on an issued US patent held by Thomas Jefferson University, US 10,022,506.

Jefferson is currently pursuing partnership opportunities for this device. For further information, please click here.

Jefferson_logo_500w

 

 

 

medtech_mindset_global_subscribe_site_logo_brain

Subscribe to MedTech Mindset!

Receive the latest industry insights, news, podcasts, videos, and events for the medtech audience from your friends at Archimedic (average 2 emails monthly).

Medtech Leaders Trust Archimedic